Developer docs
API playgroundTry for free, no card

Search company profiles

Accurus Biosciences

Full company profile

uuid000jb2w

Namestring
Accurus Biosciences
Legal namestring
Accurus Biosciences, Inc.
Websiteurl
accurusbio.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Accurus Biosciences, Inc. is a privately held contract research organization headquartered at 2600 Hilltop Drive in Richmond, California (San Francisco Bay Area), focused on therapeutic antibody discovery and mammalian protein expression services for pharmaceutical and biotechnology companies. The company was founded by Dr. Richard Zhang (Chief Executive Officer) and Dr. Haishan Lin (Co-founder), both industry veterans with over 20 years of experience developing proteins and antibodies for therapeutic applications. The workforce is small (1-10 employees) and the company is not publicly listed; no parent organization, institutional funding rounds, or ownership changes are disclosed in the available data.

The company's core technology is built around mammalian protein expression platforms using CHO and HEK293 cells, supported by proprietary expression vector systems, a highly efficient electrofusion-based hybridoma generation process, and single-cell cloning by FACS. Services span the full therapeutic antibody workflow — therapeutic antibody discovery (hybridoma, screening by ELISA/FACS/functional assays, hybridoma sequencing), recombinant protein and antibody production (transient HEK293 and stable CHO), stable cell line generation (CHO, HEK293, MDCK, NS0), antibody humanization, antibody and protein engineering (hot spot removal, effector function optimization, bispecifics, half-life extension), cell-based assays, and molecular biology — with documented turnarounds of 3-6 weeks for recombinant proteins and 8-10 weeks for stable cell lines. Accurus also sells a catalog of recombinant proteins, research-grade monoclonal antibodies (including clones against CLDN18.2, CD47, DDR1, EGFR, HER2, FOLR1, TIGIT, RNF43, B7-H3, B7-H4, CCR8), and pre-generated stable cell lines.

Accurus operates a hybrid go-to-market model: catalog products are sold online via a direct e-commerce storefront with global cold-chain shipment, while custom services (antibody discovery, humanization, engineering, stable cell line generation) are quote-based and handled through direct inquiry. Pricing for products ranges from roughly $175 to $875 per antibody aliquot and $4,000 to $7,500 per recombinant protein or stable cell pool, with engineering and large-scale services priced on inquiry. Revenue derives from three streams — contract research services, catalog research product sales, and antibody technology licensing — the last demonstrated by a January 2024 exclusive worldwide licensing agreement with ImmPACT Bio covering a designated CLDN18.2 antibody for CAR T-cell therapy development. No financial terms, revenue figures, or backlog disclosures are available in the source material.

Short descriptiontext

Accurus Biosciences is a privately held Bay Area contract research organization offering therapeutic antibody discovery, mammalian recombinant protein production, stable cell line generation, and antibody engineering services and catalog products to pharmaceutical and biotechnology clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRichmond, United States
HQ citystring
Richmond
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic antibody discovery, recombinant protein production, stable cell line generation, antibody engineering services, biologics contract research
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biologics Contract Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services
TypeProfessional Services
Description

Fee-for-service therapeutic antibody discovery, recombinant protein production, stable cell line generation, antibody engineering, and cell-based assay services sold to pharma and biotech companies.

accurusbio.com
2Research Products
TypeOne Time License
Description

Sale of catalog products including recombinant proteins, antibodies, and stable cell lines for research use.

accurusbio.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of antibody intellectual property (e.g., CLDN18.2 antibody) to partners for therapeutic development.

accurusbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details11 tiers
1Recombinant Protein Transient Production (HEK293)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

0.1L: $4,200; 0.3L: $4,800; 0.6L: $5,500; 1L: $6,200; >1L: Inquire

accurusbio.com
2Recombinant Protein Stable Production (CHO)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

0.1L: $6,000; 0.3L: $6,500; 0.6L: $7,000; 1L: $7,500; >1L: Inquire

accurusbio.com
3Recombinant Antibody Transient Production (HEK293)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

0.1L: $4,200; 0.3L: $4,800; 0.6L: $5,500; 1L: $6,200; >1L: Inquire

accurusbio.com
4Recombinant Antibody Stable Production (CHO)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

0.1L: $6,000; 0.3L: $6,500; 0.6L: $7,000; 1L: $7,500; >1L: Inquire

accurusbio.com
5Membrane Protein Transient Expression (HEK293)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

0.1L: $4,000; 0.3L: $4,500; 0.6L: $5,000; 1L: $5,600; >1L: Inquire

accurusbio.com
6Antibody Engineering Services
ModelOtherBilling cadencePay-as-you-go
Notes

Expression optimization, hot spot removal, effector function optimization, bispecific antibodies: Please inquire

accurusbio.com
7Protein Engineering Services
ModelOtherBilling cadencePay-as-you-go
Notes

Half-life extension, mutagenesis, epitope tagging, fusion protein: Please inquire

accurusbio.com
8Stable Cell Line Generation Services
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Suspension CHO/HEK293: $7,500; Adherent CHO-K1/HEK293: $7,500; NS0: $8,500; MDCK II: $8,500; Custom: Inquire

accurusbio.com
9Antibody Products (Research Use)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100µg: $175-$385; 200µg: $285-$525; 500µg: $525-$875; PE-conjugated: $350

accurusbio.com
10Stable Cell Line Products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Typically 2 vials: $3,950-$6,000 depending on cell line type

accurusbio.com
11Isotype Control (Human IgG4)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100µg: $210; 1mg: $450

accurusbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Accurus Biosciences is a contract research organization (CRO) that provides therapeutic antibody discovery, recombinant protein and antibody production in mammalian systems (CHO and HEK293), stable cell line generation, antibody humanization, antibody and protein engineering, cell-based assays, and molecular biology services to pharmaceutical and biotechnology companies. The company also manufactures and sells catalog research products including recombinant proteins, monoclonal antibodies (anti-CLDN18.2, anti-CD47, anti-DDR1, anti-EGFR, anti-HER2, anti-TIGIT and others), pre-made stable cell lines, and mammalian cell transfection reagents. Services are delivered from its Richmond, California facility with catalog pricing for standard offerings and quote-based pricing for custom engagements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Purity >95% for recombinant proteins and antibodies as determined by SDS-PAGE or HPLC
+3 more records
Product overview1 text field

Accurus Biosciences is a protein therapeutics discovery service company offering a comprehensive suite of services encompassing therapeutic antibody discovery, recombinant protein and antibody production (both transient and stable expression in CHO and HEK293 cells), stable cell line generation (using CHO-S, HEK293, MDCK, NS0, and EL4 host cells), antibody and protein engineering (including bispecific antibodies, hot spot removal, and half-life extension), antibody humanization, cell-based assays, and molecular biology services. The company also manufactures and sells physical products including recombinant proteins, antibodies (such as anti-CLDN18.2, anti-CD47, anti-DDR1, anti-EGFR, anti-HER2, anti-TIGIT antibodies), and pre-generated stable cell lines. Services are offered as standalone offerings or integrated packages, with catalog-based pricing and custom service options.

Product and service12 records
1Therapeutic Antibody Discovery
CategoryCRO service
Description

Full-service therapeutic antibody lead discovery using proprietary hybridoma electrofusion, antigen design and immunization, screening by ELISA/FACS/functional assays, hybridoma sequencing, and chimeric antibody production. Sold to pharma and biotech clients seeking antibody leads for therapeutic development.

2Recombinant Protein and Antibody Production
CategoryCRO service
Description

High-quality mammalian protein expression and purification services using proprietary production cell lines and expression vectors, supporting both transient (HEK293) and stable (CHO) expression at scales from 0.1L to >1L. Delivered to pharma, biotech, and academic customers with 3–6 week turnarounds and >95% purity.

3Stable Cell Line Generation
4Antibody and Protein Engineering
CategoryCRO service
Description

Engineering services covering antibody expression optimization, CDR/framework hot spot removal, Fc effector function optimization (CDC, ADCC, phagocytosis), bispecific antibody design (scFv-scFv, antibody-scFv, heterodimeric IgGs), protein half-life extension (Fc/HSA/PEG fusions), mutagenesis, and epitope tagging. Sold to therapeutic antibody and protein developers.

5Antibody Humanization
CategoryCRO service
Description

Humanization of monoclonal antibody leads and molecular engineering for optimal therapeutic properties and function. Sold to antibody developers preparing candidates for clinical development.

6Cell-Based Assays
7Molecular Biology Services
8Recombinant Proteins (catalog)
9Research Antibodies (catalog)
10Pre-made Stable Cell Lines (catalog)
11Mammalian Cell Transfection and Expression Reagents
12CLDN18.2 Antibody Out-licensing Program
CategoryTherapeutic antibody IP licensing
Description

Out-licensing of Accurus' proprietary CLDN18.2 monoclonal antibody portfolio (clones D10C, E9, T158S2 and others) to partners for therapeutic development, including the January 2024 exclusive worldwide license to ImmPACT Bio for CAR T-cell therapy applications targeting solid tumors.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1ImmPACT Bio
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-16
Description

Accurus Biosciences has granted exclusive worldwide rights to ImmPACT Bio to develop and commercialize next generation cell therapies using a designated antibody from Accurus' CLDN18.2 antibody portfolio. Accurus retains the rights to develop and commercialize its CLDN18.2 antibody portfolio for all non-cell based therapeutic applications. The partnership enables ImmPACT Bio to leverage Accurus' potentially best-in-class CLDN18.2 antibody for CAR T-cell therapy development targeting solid tumors.

accurusbio.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vancouver-based antibody discovery CRO/platform combining proprietary screening with mammalian expression for therapeutic antibody programs. Directly comparable in service offering (antibody discovery → engineering) and target customer base (pharma/biotech).

TypeDirect peer
Description

Specialty CRO offering therapeutic antibody discovery, custom protein production, and cell line generation. Closely comparable in service mix (hybridoma, recombinant antibodies, stable cell lines) and in serving biotech/pharma customers.

TypeBroad incumbent
Description

Large life-science services provider offering gene synthesis, recombinant protein/antibody production, and cell line engineering. Overlaps Accurus' catalog products and custom services at much larger scale.

TypeBroad incumbent
Description

Global biologics CRO/CDMO with end-to-end discovery through manufacturing services including antibody discovery, protein production, and stable cell line generation. Comparable service stack and customer set.

TypeBroad incumbent
Description

Global CDMO offering mammalian protein production and cell line development services. Comparable in CHO-based expression, stable cell line generation, and antibody manufacturing capabilities.

TypeBroad incumbent
Description

Major biopharmaceutical CDMO with biologics capabilities including cell line development and biotherapeutic protein production. Competes in the same upstream mammalian expression and cell line services space.

TypeBroad incumbent
Description

Discovery and bioanalytical services arm of Eurofins offering antibody and protein services. Comparable in CRO services for pharma/biotech but at significantly larger scale and broader scope.

TypeEmerging player
Description

Mid-sized CRO focused on custom monoclonal antibody development, hybridoma generation, and protein production. Comparable niche CRO serving similar biotech customers with similar service mix.

TypeEmerging player
Description

Specialty CRO offering antibody discovery (hybridoma, phage display), protein engineering, and cell line services. Comparable scope and target customer profile, though with broader modality coverage.

TypeEmerging player
Description

Specialty CRO offering recombinant protein and antibody production in mammalian systems plus antibody engineering services. Closely comparable in service offering, host systems (CHO/HEK293), and customer profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accurus Biosciences

Biologics Contract Research Servicesaccurusbio.com

Accurus Biosciences is a privately held Bay Area contract research organization offering therapeutic antibody discovery, mammalian recombinant protein production, stable cell line generation, and antibody engineering services and catalog products to pharmaceutical and biotechnology clients.

What Accurus Biosciences does

Accurus Biosciences, Inc. is a privately held contract research organization headquartered at 2600 Hilltop Drive in Richmond, California (San Francisco Bay Area), focused on therapeutic antibody discovery and mammalian protein expression services for pharmaceutical and biotechnology companies. The company was founded by Dr. Richard Zhang (Chief Executive Officer) and Dr. Haishan Lin (Co-founder), both industry veterans with over 20 years of experience developing proteins and antibodies for therapeutic applications. The workforce is small (1-10 employees) and the company is not publicly listed; no parent organization, institutional funding rounds, or ownership changes are disclosed in the available data.

The company's core technology is built around mammalian protein expression platforms using CHO and HEK293 cells, supported by proprietary expression vector systems, a highly efficient electrofusion-based hybridoma generation process, and single-cell cloning by FACS. Services span the full therapeutic antibody workflow — therapeutic antibody discovery (hybridoma, screening by ELISA/FACS/functional assays, hybridoma sequencing), recombinant protein and antibody production (transient HEK293 and stable CHO), stable cell line generation (CHO, HEK293, MDCK, NS0), antibody humanization, antibody and protein engineering (hot spot removal, effector function optimization, bispecifics, half-life extension), cell-based assays, and molecular biology — with documented turnarounds of 3-6 weeks for recombinant proteins and 8-10 weeks for stable cell lines. Accurus also sells a catalog of recombinant proteins, research-grade monoclonal antibodies (including clones against CLDN18.2, CD47, DDR1, EGFR, HER2, FOLR1, TIGIT, RNF43, B7-H3, B7-H4, CCR8), and pre-generated stable cell lines.

Accurus operates a hybrid go-to-market model: catalog products are sold online via a direct e-commerce storefront with global cold-chain shipment, while custom services (antibody discovery, humanization, engineering, stable cell line generation) are quote-based and handled through direct inquiry. Pricing for products ranges from roughly $175 to $875 per antibody aliquot and $4,000 to $7,500 per recombinant protein or stable cell pool, with engineering and large-scale services priced on inquiry. Revenue derives from three streams — contract research services, catalog research product sales, and antibody technology licensing — the last demonstrated by a January 2024 exclusive worldwide licensing agreement with ImmPACT Bio covering a designated CLDN18.2 antibody for CAR T-cell therapy development. No financial terms, revenue figures, or backlog disclosures are available in the source material.

Accurus Biosciences firmographics

Firmographics
Name
Accurus Biosciences
Legal name
Accurus Biosciences, Inc.
Website
https://accurusbio.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Accurus Biosciences is a privately held Bay Area contract research organization offering therapeutic antibody discovery, mammalian recombinant protein production, stable cell line generation, and antibody engineering services and catalog products to pharmaceutical and biotechnology clients.
Ownership category
akta.pro rank

Accurus Biosciences industry classification

Industry
Product category
Biologics Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Therapeutic antibody discovery
  • Recombinant protein production
  • Stable cell line generation
  • Antibody engineering services
  • Biologics contract research

Where Accurus Biosciences is headquartered

Location

Headquarters

HQ city
Richmond
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Accurus Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Research Services: Fee-for-service therapeutic antibody discovery, recombinant protein production, stable cell line generation, antibody engineering, and cell-based assay services sold to pharma and biotech companies.
  2. Research Products: Sale of catalog products including recombinant proteins, antibodies, and stable cell lines for research use.
  3. Technology Licensing: Licensing of antibody intellectual property (e.g., CLDN18.2 antibody) to partners for therapeutic development.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goRecombinant Protein Transient Production (HEK293)
Unit PricingPay-as-you-goRecombinant Protein Stable Production (CHO)
Unit PricingPay-as-you-goRecombinant Antibody Transient Production (HEK293)
Unit PricingPay-as-you-goRecombinant Antibody Stable Production (CHO)
Unit PricingPay-as-you-goMembrane Protein Transient Expression (HEK293)
OtherPay-as-you-goAntibody Engineering Services
OtherPay-as-you-goProtein Engineering Services
Unit PricingPay-as-you-goStable Cell Line Generation Services
Unit PricingPay-as-you-goAntibody Products (Research Use)
Unit PricingPay-as-you-goStable Cell Line Products
Unit PricingPay-as-you-goIsotype Control (Human IgG4)

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Accurus Biosciences product offering

Product offering

Core offering

Accurus Biosciences is a contract research organization (CRO) that provides therapeutic antibody discovery, recombinant protein and antibody production in mammalian systems (CHO and HEK293), stable cell line generation, antibody humanization, antibody and protein engineering, cell-based assays, and molecular biology services to pharmaceutical and biotechnology companies. The company also manufactures and sells catalog research products including recombinant proteins, monoclonal antibodies (anti-CLDN18.2, anti-CD47, anti-DDR1, anti-EGFR, anti-HER2, anti-TIGIT and others), pre-made stable cell lines, and mammalian cell transfection reagents. Services are delivered from its Richmond, California facility with catalog pricing for standard offerings and quote-based pricing for custom engagements.

Product overview

Accurus Biosciences is a protein therapeutics discovery service company offering a comprehensive suite of services encompassing therapeutic antibody discovery, recombinant protein and antibody production (both transient and stable expression in CHO and HEK293 cells), stable cell line generation (using CHO-S, HEK293, MDCK, NS0, and EL4 host cells), antibody and protein engineering (including bispecific antibodies, hot spot removal, and half-life extension), antibody humanization, cell-based assays, and molecular biology services. The company also manufactures and sells physical products including recombinant proteins, antibodies (such as anti-CLDN18.2, anti-CD47, anti-DDR1, anti-EGFR, anti-HER2, anti-TIGIT antibodies), and pre-generated stable cell lines. Services are offered as standalone offerings or integrated packages, with catalog-based pricing and custom service options.

Differentiator

Problem solved

Functional benefit

Products and services

  • Therapeutic Antibody Discovery Full-service therapeutic antibody lead discovery using proprietary hybridoma electrofusion, antigen design and immunization, screening by ELISA/FACS/functional assays, hybridoma sequencing, and chimeric antibody production. Sold to pharma and biotech clients seeking antibody leads for therapeutic development.
  • Recombinant Protein and Antibody Production High-quality mammalian protein expression and purification services using proprietary production cell lines and expression vectors, supporting both transient (HEK293) and stable (CHO) expression at scales from 0.1L to >1L. Delivered to pharma, biotech, and academic customers with 3–6 week turnarounds and >95% purity.
  • Stable Cell Line Generation
  • Antibody and Protein Engineering Engineering services covering antibody expression optimization, CDR/framework hot spot removal, Fc effector function optimization (CDC, ADCC, phagocytosis), bispecific antibody design (scFv-scFv, antibody-scFv, heterodimeric IgGs), protein half-life extension (Fc/HSA/PEG fusions), mutagenesis, and epitope tagging. Sold to therapeutic antibody and protein developers.
  • Antibody Humanization Humanization of monoclonal antibody leads and molecular engineering for optimal therapeutic properties and function. Sold to antibody developers preparing candidates for clinical development.
  • Cell-Based Assays
  • Molecular Biology Services
  • Recombinant Proteins (catalog)
  • Research Antibodies (catalog)
  • Pre-made Stable Cell Lines (catalog)
  • Mammalian Cell Transfection and Expression Reagents
  • CLDN18.2 Antibody Out-licensing Program Out-licensing of Accurus' proprietary CLDN18.2 monoclonal antibody portfolio (clones D10C, E9, T158S2 and others) to partners for therapeutic development, including the January 2024 exclusive worldwide license to ImmPACT Bio for CAR T-cell therapy applications targeting solid tumors.

Quantifiable outcome

  • Purity >95% for recombinant proteins and antibodies as determined by SDS-PAGE or HPLC
  • +3 more outcomes

Companies that use Accurus Biosciences

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Accurus Biosciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Accurus Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ImmPACT BiocoreOEM/ Whitelabel/ Licensing Partner · 16 January 2024Accurus Biosciences has granted exclusive worldwide rights to ImmPACT Bio to develop and commercialize next generation cell therapies using a designated antibody from Accurus' CLDN18.2 antibody portfolio. Accurus retains the rights to develop and commercialize its CLDN18.2 antibody portfolio for all non-cell based therapeutic applications. The partnership enables ImmPACT Bio to leverage Accurus' potentially best-in-class CLDN18.2 antibody for CAR T-cell therapy development targeting solid tumors.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Accurus Biosciences competitors and assessment

Company assessment

Direct peers

  • AbCellera Biologics: Vancouver-based antibody discovery CRO/platform combining proprietary screening with mammalian expression for therapeutic antibody programs. Directly comparable in service offering (antibody discovery → engineering) and target customer base (pharma/biotech).
  • ImmunoPrecise Antibodies: Specialty CRO offering therapeutic antibody discovery, custom protein production, and cell line generation. Closely comparable in service mix (hybridoma, recombinant antibodies, stable cell lines) and in serving biotech/pharma customers.

Broad incumbents

  • GenScript: Large life-science services provider offering gene synthesis, recombinant protein/antibody production, and cell line engineering. Overlaps Accurus' catalog products and custom services at much larger scale.
  • WuXi Biologics: Global biologics CRO/CDMO with end-to-end discovery through manufacturing services including antibody discovery, protein production, and stable cell line generation. Comparable service stack and customer set.
  • Lonza: Global CDMO offering mammalian protein production and cell line development services. Comparable in CHO-based expression, stable cell line generation, and antibody manufacturing capabilities.
  • Catalent: Major biopharmaceutical CDMO with biologics capabilities including cell line development and biotherapeutic protein production. Competes in the same upstream mammalian expression and cell line services space.
  • Eurofins Discovery: Discovery and bioanalytical services arm of Eurofins offering antibody and protein services. Comparable in CRO services for pharma/biotech but at significantly larger scale and broader scope.

Emerging players

  • ProMab Biotechnologies: Mid-sized CRO focused on custom monoclonal antibody development, hybridoma generation, and protein production. Comparable niche CRO serving similar biotech customers with similar service mix.
  • Creative Biolabs: Specialty CRO offering antibody discovery (hybridoma, phage display), protein engineering, and cell line services. Comparable scope and target customer profile, though with broader modality coverage.
  • ProteoGenix: Specialty CRO offering recombinant protein and antibody production in mammalian systems plus antibody engineering services. Closely comparable in service offering, host systems (CHO/HEK293), and customer profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Accurus Biosciences social profiles

Digital presence

Accurus Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accurus Biosciences leadership team

Management profile

Number of profiles

Profiles2 records

Accurus Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accurus Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accurus Biosciences

What does Accurus Biosciences do?

Accurus Biosciences is a contract research organization (CRO) that provides therapeutic antibody discovery, recombinant protein and antibody production in mammalian systems (CHO and HEK293), stable cell line generation, antibody humanization, antibody and protein engineering, cell-based assays, and molecular biology services to pharmaceutical and biotechnology companies. The company also manufactures and sells catalog research products including recombinant proteins, monoclonal antibodies (anti-CLDN18.2, anti-CD47, anti-DDR1, anti-EGFR, anti-HER2, anti-TIGIT and others), pre-made stable cell lines, and mammalian cell transfection reagents. Services are delivered from its Richmond, California facility with catalog pricing for standard offerings and quote-based pricing for custom engagements.

Is Accurus Biosciences a public or private company?

Accurus Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Accurus Biosciences founded?

Accurus Biosciences was founded in -1. It employs 1 to 10 people.

Where is Accurus Biosciences based?

Accurus Biosciences is headquartered in Richmond, United States, in the North America region.

How does Accurus Biosciences make money?

Three revenue lines are on record. Contract Research Services are the primary driver. The others are research Products and technology Licensing.

Who are Accurus Biosciences's main competitors?

Direct peers on record are AbCellera Biologics and ImmunoPrecise Antibodies. Broad incumbents are GenScript, WuXi Biologics, Lonza, Catalent and Eurofins Discovery. Emerging players are ProMab Biotechnologies, Creative Biolabs and ProteoGenix.

Does Accurus Biosciences have an API?

No public API is recorded for Accurus Biosciences.

What industry is Accurus Biosciences in?

Accurus Biosciences's product category is Biologics Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales